New drug combo aims to tame tough blood cancer when standard treatment Isn't enough
Disease control
Recruiting now
This study is for people with myelofibrosis, a serious bone marrow cancer, who are not getting the best results from their current standard medication (ruxolitinib). It will test if adding a new drug called navtemadlin to the standard treatment works better and is safe. About 600…
Phase: PHASE3 • Sponsor: Kartos Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC